quinazolines has been researched along with isoxazoles in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (22.22) | 18.7374 |
| 1990's | 3 (11.11) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 14 (51.85) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Diamantis, W; Ludwig, BJ; Sofia, RD | 1 |
| Ballard, F; Kucharczyk, N; Myers, G; Sofia, RD; Yang, J | 1 |
| Dejneka, T; Ludwig, BJ; Reisner, DB; Simon, E; Sofia, RD | 1 |
| Douglas, JF; Edelson, J; Ludwig, BJ | 1 |
| Banerjee, BN; Ivins, NJ; Ludwig, BJ; Sofia, RD | 1 |
| Diamantis, W; Edelson, J; Gordon, R; Ludwig, BJ; Sofia, RD | 1 |
| Amico-Roxas, M; Bajardi, ML; Caruso, A; Cutuli, V; Daidone, G; Plescia, S; Raffa, D | 1 |
| Daidone, G; Plescia, S; Raffa, D; Schillaci, D | 1 |
| Daidone, G; Maggio, B; Plescia, F; Raffa, D; Schillaci, D | 1 |
| Sipp, D | 1 |
| Kudo, S | 1 |
| Chida, K; Miyazaki, K; Ogura, T; Sugiyama, Y; Yamaguchi, T | 1 |
| Clarke, AR; Maughan, TS; Shaw, PH | 1 |
| Abraham, S; Apuy, JL; Armstrong, RC; Ator, MA; Bhagwat, S; Campbell, BT; Chao, Q; Cramer, MD; Dorsey, BD; Ezawa, M; Faraoni, R; Gardner, MF; Ghose, AK; Gibney, M; Gitnick, D; Gunawardane, RN; Herbertz, T; Holladay, MW; Hua, H; Insko, DE; James, J; Jones-Bolin, S; Lai, AG; Nepomuceno, RR; Rowbottom, MW; Ruggeri, B; Setti, E; Sprankle, KG; Struss, B; Tran, L; Valenta, I; Williams, M | 1 |
| Chekaluk, Y; Du, J; Gray, NS; Guo, Y; Kwiatkowski, DJ; Wu, CL; Zhang, J | 1 |
| Kittakoop, P; Mahidol, C; Ruchirawat, S | 1 |
| Ding, Y; Shen, Q; Wild, C; Ye, N; Zhou, J | 1 |
| Fernandes, J; Jampol, LM; Johnson, ML; Mets, M; Munk, MR; Patel, JD | 1 |
| Parveen, G; Rahman, MU; Rathore, A; Shahar Yar, M; Siddiqui, AA | 1 |
| Lu, CZ; Wu, X; Yong, JP | 1 |
| Boeckh, M; Murphy, WJ; Peggs, KS | 1 |
| Asano, H; Furukawa, M; Hashida, S; Kanazawa, S; Maki, Y; Miyoshi, S; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Yamamoto, H | 1 |
| Baek, IJ; Bivona, TG; Choi, CM; Choi, SH; Choi, YJ; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS | 1 |
| Hart, EM; Johnson, ML; Kris, MG; Patel, JD; Rademaker, AW; Riely, GJ; Weitner, BB; Yu, HA | 1 |
| Chen, DQ; Ding, J; Geng, MY; Liu, HC; Shen, AJ; Shen, JK; Sun, JY; Wang, X; Wang, YQ; Xiong, B; Zhang, MM; Zheng, M | 1 |
| Akin, JW; Brännström, M; Choi, Y; Curry, TE; Jo, M; Rosewell, KL | 1 |
| Hah, JM; Im, D; Jang, M; Kim, J; Moon, H; Oh, Y | 1 |
3 review(s) available for quinazolines and isoxazoles
| Article | Year |
|---|---|
[Drug induced lung injuries in Japanese population].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Asian People; Bleomycin; Gefitinib; Genetic Predisposition to Disease; Humans; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial; Pulmonary Alveoli; Quinazolines; Racial Groups | 2006 |
Alkaloids as important scaffolds in therapeutic drugs for the treatments of cancer, tuberculosis, and smoking cessation.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antitubercular Agents; Humans; Isoxazoles; Molecular Structure; Pyridines; Quinazolines; Smoking Cessation | 2014 |
Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.
Topics: Acetates; Adoptive Transfer; Animals; Antiviral Agents; Benzimidazoles; Cell- and Tissue-Based Therapy; Clinical Trials, Phase III as Topic; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Hematopoietic Stem Cell Transplantation; Humans; Isoxazoles; Killer Cells, Natural; Leflunomide; Mice; Organophosphonates; Quinazolines; Ribonucleosides; T-Lymphocytes | 2015 |
1 trial(s) available for quinazolines and isoxazoles
| Article | Year |
|---|---|
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Molecular Chaperones; Mutation; Quinazolines; Resorcinols; Treatment Outcome | 2015 |
23 other study(ies) available for quinazolines and isoxazoles
| Article | Year |
|---|---|
Pharmacological properties of 2,3-dihydro-9H-isoxazolo [3,2-b] quinazolin-9-one (W-2429. Part 1: Analgesic, antipyretic and antiedema activity.
Topics: Administration, Oral; Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Aspirin; Body Temperature; Dextropropoxyphene; Drug Interactions; Drug Tolerance; Edema; Fever; Humans; Injections, Intravenous; Isoxazoles; Lethal Dose 50; Male; Mice; Narcotic Antagonists; Oxazoles; Quinazolines; Rats; Substance-Related Disorders; Time Factors | 1977 |
The disposition of 3-methyl-2,3-dihydro-9H-isoxazolo[3,2-b]-quinazolin-9-one (W-2451).
Topics: Analgesics; Animals; Biotransformation; Blood Proteins; Dogs; Haplorhini; Humans; In Vitro Techniques; Isoxazoles; Liver; Male; Oxazoles; Quinazolines; Rats; Species Specificity; Time Factors; Tissue Distribution | 1979 |
2,3-Dihydro-9H-isoxazolo[3,2-b]quinazolin-9-ones and 3,4-dihydro-(1,2)-oxazino [3,2-b]quinazolin-10(2H)-ones.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Isoxazoles; Oxazines; Quinazolines; Rats; Structure-Activity Relationship | 1977 |
Absorption, distribution and metabolic fate of 2,3-dihydro-9H-isoxazolo-[3,2-b]quinazolin-9-one (W2429).
Topics: Administration, Oral; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Blood Proteins; Dogs; Humans; Intestinal Absorption; Isoxazoles; Kinetics; Male; Mice; Oxazoles; Protein Binding; Quinazolines; Rats | 1977 |
Toxicological investigation of 2,3-dihydro-9H-isoxazolo[3,2-b]quinazolin-9-one (W-2429). Acute and subacute toxicity in mice, rats and dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Cell Count; Blood Chemical Analysis; Body Weight; Dogs; Female; Isoxazoles; Lethal Dose 50; Male; Mice; Organ Size; Oxazoles; Quinazolines; Rats; Spermatogenesis; Time Factors | 1977 |
Pharmacological properties of 2,3-dihydro-9H-isoxazolo[3,2-b]-quinazolin-9-one (W-2429. Part 2: General pharmacological investigation.
Topics: Anesthetics, Local; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents, Tricyclic; Antitussive Agents; Cats; Diuresis; Dogs; Enzyme Induction; Female; Gastrointestinal Hemorrhage; Gastrointestinal Motility; Guinea Pigs; Hemodynamics; Isoxazoles; Male; Mice; Motor Activity; Muscle Contraction; Muscle, Smooth; Oxazoles; Postural Balance; Prostaglandin-Endoperoxide Synthases; Quinazolines; Rabbits; Rats; Respiration; Sleep; Stomach Ulcer; Time Factors | 1977 |
Synthesis and pharmacological study of some 3-(isoxazol-5-yl)-quinazolin-4(3H)-ones.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Isoxazoles; Male; Mice; Quinazolines; Rats; Rats, Sprague-Dawley; Stomach Ulcer | 1992 |
Synthesis and antifungal evaluation of some 3-(3-methyl-5-isoxazolyl)-2-styrylquinazolin-4(3H)-ones.
Topics: Antifungal Agents; Candida; Candida albicans; Fungi; Isoxazoles; Microbial Sensitivity Tests; Paecilomyces; Quinazolines; Styrenes | 1991 |
Synthesis of new 3-(3-phenyl-isoxazol-5-yl) or 3-[(3-phenyl-isoxazol-5-yl)-amino] substituted 4(3H)-quinazolinone derivatives with antineoplastic activity.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Isoxazoles; Magnetic Resonance Spectroscopy; Quinazolines; Spectrophotometry, Infrared; Tumor Cells, Cultured | 1999 |
'Fast-track' drug approvals hit speed bumps in Japan.
Topics: Drug Approval; Drug Evaluation; Gefitinib; Isoxazoles; Japan; Leflunomide; Public Policy; Quinazolines | 2004 |
[Diagnosis of and therapy for diffuse lung diseases (discussion)].
Topics: Alveolitis, Extrinsic Allergic; Biomarkers; Bronchiolitis; Gefitinib; Humans; Isoxazoles; Leflunomide; Lung Diseases, Interstitial; Quinazolines; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed | 2006 |
Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Gefitinib; Genes, APC; Intestinal Neoplasms; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; Tumor Burden | 2011 |
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (B
Topics: Administration, Oral; Animals; Binding, Competitive; Cell Line, Tumor; Cell Proliferation; Dogs; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles; Macaca fascicularis; Male; Mice; Mice, Nude; Microsomes, Liver; Models, Molecular; Mutation; Neoplasm Transplantation; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Quinazolines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2012 |
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Topics: Afatinib; Antibiotics, Antineoplastic; Cell Line, Tumor; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lapatinib; Loss of Heterozygosity; Naphthyridines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; Resorcinols; Signal Transduction; Sirolimus; Tuberous Sclerosis Complex 1 Protein; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
Small molecule inhibitors targeting activator protein 1 (AP-1).
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Benzophenones; Biological Products; Humans; Inflammation; Isoxazoles; Maleimides; Molecular Targeted Therapy; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction; Small Molecule Libraries; Transcription Factor AP-1; Transcription Factors | 2014 |
Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy.
Topics: Adenocarcinoma; Aged; Autoantibodies; Autoantigens; Electroretinography; Erlotinib Hydrochloride; HSP90 Heat-Shock Proteins; Humans; Infusions, Intravenous; Isoxazoles; Lung Neoplasms; Male; Night Blindness; Paraneoplastic Syndromes, Ocular; Phosphopyruvate Hydratase; Quinazolines; Resorcinols; Retina; Tomography, Optical Coherence; Visual Acuity | 2014 |
Synthesis and antihypertensive screening of new derivatives of quinazolines linked with isoxazole.
Topics: Animals; Antihypertensive Agents; Drug Evaluation, Preclinical; Epinephrine; Humans; Hypertension; Isoxazoles; Molecular Structure; Quinazolines; Rats; Structure-Activity Relationship | 2014 |
Potential anticancer agents. I. Synthesis of isoxazole moiety containing quinazoline derivatives and preliminarily in vitro anticancer activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Isoxazoles; MCF-7 Cells; Quinazolines; Structure-Activity Relationship | 2015 |
Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA End-Joining Repair; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols | 2015 |
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
Topics: Animals; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Resorcinols; Xenograft Model Antitumor Assays | 2015 |
Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heterografts; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Transplantation; Oxazoles; Quinazolines; Resorcinols | 2016 |
FOS, a Critical Downstream Mediator of PGR and EGF Signaling Necessary for Ovulatory Prostaglandins in the Human Ovary.
Topics: Adult; Benzophenones; Cells, Cultured; Chorionic Gonadotropin; Dinoprostone; Epidermal Growth Factor; Female; Humans; Isoxazoles; Mifepristone; Ovarian Follicle; Ovulation; Primary Cell Culture; Progesterone; Proto-Oncogene Proteins c-fos; Quinazolines; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Tyrphostins; Up-Regulation | 2018 |
Discovery of 5-methyl-
Topics: Dose-Response Relationship, Drug; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Isoxazoles; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2020 |